Literature DB >> 3133689

Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.

Y Kasvikis1, I M Marks.   

Abstract

Forty-nine obsessive-compulsive ritualisers completed a double-blind controlled study of clomipramine and exposure therapy. More severely ill patients allowed higher doses of medication to be prescribed and had higher plasma levels of both clomipramine and desmethylclomipramine. Exposure instructions had a strong effect, whereas the clomipramine effect was small and short-lived. Plasma levels of desmethylclomipramine but not of clomipramine correlated with outcome at weeks 8 and 17. There was no evidence of a therapeutic window for either clomipramine or its metabolite. Patients' physical complaints before treatment correlated positively with depression and anxiety, especially sexual difficulties. Dry mouth, as a side effect, was most evidently related to clomipramine and its usefulness in monitoring drug compliance for patients on clomipramine is reaffirmed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133689     DOI: 10.1007/bf00212778

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Standardised assessment and recording of depressive symptoms.

Authors:  M Hamilton
Journal:  Psychiatr Neurol Neurochir       Date:  1969 Mar-Apr

2.  Effects of imaginal exposure to feared disasters in obsessive-compulsive checkers.

Authors:  E B Foa; G Steketee; R M Turner; S C Fischer
Journal:  Behav Res Ther       Date:  1980

3.  Clomipramine: plasma levels and clinical effects.

Authors:  N Reisby; L F Gram; P Bech; F Sihm; O Krautwald; J Elley; J Ortmann; J Christiansen
Journal:  Commun Psychopharmacol       Date:  1979

4.  Severe agoraphobia: a controlled prospective trial of behaviour therapy.

Authors:  M G Gelder; I M Marks
Journal:  Br J Psychiatry       Date:  1966-03       Impact factor: 9.319

5.  Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desimipramine in man in connection with chlorimipramine metabolism.

Authors:  G Laakmann; M Gugath; H J Kuss; K Zygan
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome.

Authors:  R S Stern; I M Marks; D Mawson; D K Luscombe
Journal:  Br J Psychiatry       Date:  1980-02       Impact factor: 9.319

7.  Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals.

Authors:  I M Marks; P Lelliott; M Basoglu; H Noshirvani; W Monteiro; D Cohen; Y Kasvikis
Journal:  Br J Psychiatry       Date:  1988-04       Impact factor: 9.319

8.  Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.

Authors:  P Thorén; M Asberg; B Cronholm; L Jörnestedt; L Träskman
Journal:  Arch Gen Psychiatry       Date:  1980-11

9.  Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects.

Authors:  P Thorén; M Asberg; L Bertilsson; B Mellström; F Sjöqvist; L Träskman
Journal:  Arch Gen Psychiatry       Date:  1980-11

10.  Clomipramine and exposure for chronic obsessive-compulsive rituals: III. Two year follow-up and further findings.

Authors:  D Mawson; I M Marks; L Ramm
Journal:  Br J Psychiatry       Date:  1982-01       Impact factor: 9.319

View more
  2 in total

Review 1.  Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder.

Authors:  D McTavish; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 2.  Obsessive-compulsive disorder in elderly patients.

Authors:  C W Jackson
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.